We have observed
3 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 20, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
RECOMBINANT TRIVALENT VACCINE AGAINST HUMAN INFLUENZA
COMPOSITION FOR ENHANCING TRANSGENE EXPRESSION IN EUKARYOTIC CELLS AND METHOD FOR ENHANCING PRODUCTION OF A TARGET PROTEIN ENCODED BY A TRANSGENE
METHOD OF PRODUCING A SUBSTANCE WITH ANTIMICROBIAL, ANTIVIRAL, AND IMMUNOSTIMULATORY ACTIVITIES, A SUBSTANCE AND A COMPOSITION